{"id":"lidocaine-per-embolization","safety":{"commonSideEffects":[{"rate":null,"effect":"Local injection site reactions"},{"rate":null,"effect":"Transient numbness or paresthesia"},{"rate":null,"effect":"Allergic reaction (rare)"}]},"_chembl":{"chemblId":"CHEMBL79","moleculeType":"Small molecule","molecularWeight":"234.34"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Lidocaine blocks sodium channels in nerve cell membranes, preventing depolarization and transmission of pain signals. When administered pre-embolization, it provides local anesthesia to reduce procedural pain during vascular embolization interventions. This approach allows for improved patient comfort and potentially better procedural tolerance during minimally invasive vascular procedures.","oneSentence":"Lidocaine is a local anesthetic administered before embolization procedures to reduce pain and discomfort during the interventional radiological intervention.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:37:17.399Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Pain management during embolization procedures"}]},"trialDetails":[{"nctId":"NCT06166628","phase":"NA","title":"Genicular Artery Embolization vs Nerve Ablation Intervention (GENI) for Knee Osteoarthritis","status":"RECRUITING","sponsor":"David Clinkard","startDate":"2023-12-01","conditions":"Knee Osteoarthritis","enrollment":150},{"nctId":"NCT02293447","phase":"PHASE4","title":"Intra-arterial Lidocaine for Pain Control Post Uterine Fibroid Embolization","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2014-11","conditions":"Uterine Leiomyomas","enrollment":60}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Local anesthetic","Amide-type anesthetic","Lidocaine hydrochloride","00884154"],"phase":"marketed","status":"active","brandName":"Lidocaine per-embolization","genericName":"Lidocaine per-embolization","companyName":"University Health Network, Toronto","companyId":"university-health-network-toronto","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Lidocaine per-embolization is a treatment that involves injecting lidocaine into a specific artery to block pain signals, and it has been studied as a potential treatment for conditions such as uterine leiomyomas and knee osteoarthritis. Lidocaine per-embolization works by blocking sodium channels, specifically the sodium channel alpha subunit, which are involved in the transmission of pain signals.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}